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Abstract
Most research articles presenting new data analysis methods claim that “the new
method performs better than existing methods,” but the veracity of such statements is
questionable. Our manuscript discusses and illustrates consequences of the optimistic
bias occurring during the evaluation of novel data analysis methods, that is, all biases
resulting from, for example, selection of datasets or competing methods, better ability
to fix bugs in a preferred method, and selective reporting of method variants. We
quantitatively investigate this bias using an example from epigenetic analysis:
normalization methods for data generated by the Illumina HumanMethylation450K
BeadChip microarray.
Keywords: Benchmarking, Optimistic bias, Neutral comparison study, Illumina
HumanMethylation450K BeadChip, Normalization
Background
Many studies in the biomedical sciences employ computational methods to process and
evaluate data in order to answer the research question presented. Sometimes these meth-
ods are relatively simple, such as t-tests to detect differentially expressed genes, but in
many cases the methods are complex, and there is no final “gold standard” as to which
method to apply in a given setting. Further complicating matters is that data acquisition,
data structure, and research questions themselves evolve quickly. As such, the devel-
opment of new computational methods is an active field of research, a situation which
constantly introduces new methods into the literature, often in a comparison with exist-
ing methods. Yet despite the frequency of these types of papers, there is a surprising
lack of guidance on the appropriate design and reporting of studies presenting and eval-
uating new computational methods [1, 2]. It is not clear how new methods and their
performances should be described and how studies comparing performances of meth-
ods should be designed. This absence of guidance is in strong contrast to the intensive
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decades-long discussions in the biomedical literature on the design of other types of
health science studies and the numerous resultant reporting guidelines and guidance doc-
uments developed, such as those for observational studies [3], randomized clinical trials
[4], and meta-analyses [5].
The abundance of literature introducing computational methods is often perceived as
confusing, and data analysts have difficulty keeping pace with methodological develop-
ments in their field and thus choosing the most appropriate method for their data and
question at hand [6]. In this context, benchmarking studies (i.e., systematic studies com-
paring the behaviors and performances of computational methods) [7, 8], especially those
that are neutral [9], and those that incorporate a blinding procedure [10], community
computational challenges, and meta-analyses of benchmarking studies [11] (i.e., studies
combining the results of several benchmark studies) are crucial in providing guidance for
the methods’ potential users [12].
A major issue related to the design and reporting of studies introducing new compu-
tational methods is optimistic bias: the performance of a newly introduced method is
often—intentionally or unintentionally—oversold. Though little acknowledged, publica-
tion bias likely pervades the computational literature [13]. In fear of not getting published,
researchers may feel pressure to report the superiority of their new method, succumb-
ing to the temptations of selective reporting or data dredging, practices which can lead
to significant optimistic bias with regard to the performance of their new method, a con-
sequence illustrated in several empirical studies on classification using high-dimensional
data [14, 15]. The term “self-assessment trap” has also been used to describe these
mechanisms [16, 17].
For example, authors could preferentially report the results for datasets [14] or perfor-
mance metrics [16] for which their newmethod works better than for existing ones. They
may bemore attentive to—and proficient in—choosing parameters or fixing bugs for their
method than for competing methods. For example, if a new method yields a noticeably
bad result in one analysis, the authors are likely to look for a potential bug, while they
would accept the bad result—without further investigation—if observed for a competing
method. Finally, if they develop several variants of their method and report only the vari-
ant that (perhaps by chance) performs best on the datasets and metrics used as examples,
this variant will likely perform worse on future datasets, i.e., the good performance does
not generalize. And although this bias weakens with a greater number of datasets used for
fitting and evaluation, another problemmay be that authors test their method on datasets
from contexts with which they are familiar, and failing to outline this bias in the limita-
tions. Previous studies have indicated that performance evaluation can highly depend on
the type of datasets examined [18], a source of variation perhaps revealed in later studies
involving types of datasets unanticipated by the original method’s authors.
A consequence of the conscious and unconscious decisions biasing a study intro-
ducing a new method is that subsequent comparison studies by independent authors,
“neutral” studies, often fail to replicate the superior performance of the method in ques-
tion [19]. We assessed this bias quantitatively for a class of computational methods,
namely methods to preprocess the raw data produced by the HumanMethylation450K
BeadChip (450K), a microarray used to detect the methylation levels of approximately
450,000 genetic loci [20] (many of these methods having been modified to be applicable
to the current EPIC BeadChip). Data preprocessing can crucially affect later data analysis
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[21, 22] in the context of epigenome-wide studies. Dozens of 450K preprocessingmethods
have been proposed in recent years, along with extensive comparison analyses [22], both
in papers introducing new methods and in neutral benchmark studies, an ideal situation
for investigation into the potential optimistic bias discussed here.
Results and discussion
We surveyed papers presenting new methods and checked whether these new methods
were assessed as better than existing competitors. We then investigated whether the same
pairwise comparisons, when performed in later—presumably unbiased—studies, again
evaluated the new method as better than the old. This principle is schematically illus-
trated in Fig. 1. Imagine that a method “B” is introduced in the literature some time after
a method “A” had been introduced. In the paper presenting method B, the authors com-
pare it to method A (typically, they find that B is better than A). This is what we call a
non-neutral comparison because the authors are interested in demonstrating the superi-
ority of method B. Some time later, a paper suggesting another method, “C”, is published.
The authors compare C to existing methods A and B, which implies that this study also
compares B to A, although this latter comparison is not the paper’s focus. This study is
assumed to be neutral with respect to the comparison of A and B, exactly as the later study
termed a “neutral benchmark study” in Fig. 1.
In the simplified scenario of Fig. 1, we have one non-neutral study and two neutral
studies, all comparing A and B. In the terminology commonly used in the debate on
the replication crisis, the former could be denoted as an “original study” and the latter
two as “replication studies”. Of course, in general, there may be any number of neutral
studies, not just two.Most importantly, in our survey, we did not focus on a specific pair of
Fig. 1 We examine the point in time where a method “A” exists in the literature, and a new method “B” is
introduced. In the paper presenting method B, the authors compare it to method A: a “non-neutral
comparison” (dark red color, see also Fig. 2), as method B’s authors may have some bias in presenting the
results. Some time later, a paper introducing another method, “C”, is published. The authors compare C to
existing methods A and B, which implies also a comparison of B to A, although this comparison is not the
study’s focus. This latter study is assumed to be neutral (dark blue color, see also Fig. 2) with respect to A and
B and is termed a “neutral benchmark study”
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methods, but looked for all pairs that were compared in the non-neutral study introducing
the newer one and at least one subsequent neutral study.
Note that each pair of methods thus acts as its own control, helping to avoid prob-
lems due to confounding, such as through chronological time effects (if scientific progress
works correctly, new methods are expected to be on average better than older ones,
although this is not necessarily the case in practice [23]).
We identified 27 relevant studies (see supplement for details). We extracted pairs of
methods that were compared in the non-neutral study introducing the newer of the two
and at least one subsequent study which was neutral with respect to this pair (i.e., a paper
introducing a third method or a neutral study not introducing a new method).
Some of the papers present several substudies (typically investigating different aspects
of the methods), each comparing all or a subset of the methods considered in the paper.
In a first analysis, we focused on the substudies that compare all the methods consid-
ered in the paper, i.e., we excluded the “partial substudies.” With this strategy, we found
19 pairs of methods compared both in the paper introducing the newer of the two and
in at least one subsequent paper which was neutral with respect to this pair. For each
pair and each paper, we recorded whether the newer method was ranked better than the
older method. In the second analysis, we considered substudies as independent studies,
i.e., ignored that they exist in “clusters” (the paper they come from), and did not exclude
incomplete substudies. This yielded a total of 28 pairs. For each pair and each substudy,
we again recorded whether the newer method was ranked better than the older.
The supplement provides full details on the analysis methods, and the data and R code
to generate the results.
The results are displayed in Fig. 2. In the first analysis (considering papers as unit), the
new method was ranked better than the older in 94.7% (18 of 19) of the comparisons
from non-neutral papers introducing the new method, a very high rate similar to one
detailed in a previous survey of the statistical and bioinformatics literature [9]. In neutral
comparisons (subsequent papers that were neutral with respect to the considered pair),
these same new methods outperformed 64.3% of their paired competitors (49.5 of 77
neutral comparisons, where pairs with equal performances count as 0.5). This rate lies
between the rate for non-neutral papers and the rate of 50% assumed for a method that
performs equally well as other methods. This finding suggests a noteworthy optimistic
bias in favor of new methods in the papers introducing them, but also the realization of
scientific progress, i.e., newer methods are on average superior to older.
The second analysis (considering substudies as unit) shows the same trends. The newer
method was ranked better than the older in 83.2% (136.5 of 164) of the comparisons from
non-neutral substudies, revealing that even according to biased authors, their method is
not superior in every situation. This rate is once more higher than the 61.2% (408.5 of
667) observed for neutral substudies, again suggesting optimistic bias. It is however much
lower than the 94.7% observed in the first analysis, which is in agreement with Norel et al.’s
claim that “when the number of performancemetrics is larger than two,mostmethods fail
to be the best in all categories assessed” [16]: even the overall “better” method, as judged
by the first analysis, is recognized by the authors of the better method as performing
worse in some substudies.
Our study has some limitations. We neither performed a systematic literature search
nor assessed the quality of the investigated papers, in particular the quality of the
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Fig. 2 Comparisons between 450K data normalization methods: percentages of comparisons identifying the
newer method as better than the older. The x-axis shows which two methods are being compared (see
Additional files 1 and 2 for the references of the methods, abbreviations, and any aliases used in the paper).
“Introducing” (i.e., “non-neutral”) comparisons (red dots) are those from publications introducing the new
method. “Neutral” comparisons (blue dots) are from subsequent studies written by authors who developed
neither of the methods being compared. Two analyses are presented. In the first analysis (light dots), the
percentage is calculated over papers, i.e., where the overall rank from a paper is taken as the comparison. The
percentage is thus either 0% or 100% for introducing comparisons, as for each pair there is only one
introducing study (that in which the newer method is introduced). Papers were excluded from this analysis if
individual components of the evaluation used only a subset of the methods examined in the paper (“partial
substudies”). In the second analysis (dark dots), the percentage is calculated over substudies, i.e., individual
comparisons within a paper. The “number of comparisons” refers to the number of papers (for the first
analysis, which takes papers as units) or to the number of substudies (for the second analysis, which takes
substudies as units)
performance measures, as our study is meant as illustrative. The evaluator extracting the
data could obviously not be blinded to the type of paper (non-neutral or neutral). This lack
of blindness could have slightly distorted our results, as the evaluator’s expectation was
that new methods would tend to be optimistically rated in the papers introducing them.
This expectation might have affected, for example, his (partly subjective) evaluation of
blurred or ambiguous graphical results within the papers being evaluated. Moreover, not
taken into account in our study were the sizes of the differences between method perfor-
mances: a method was considered either better or worse than the other, which obviously
leads to a loss of information and precision.
The precise definition of a “method” also presents a problem. Many of the papers
here evaluate the methods within a full “pipeline” of preprocessing, with such optional
steps as background correction and elimination of probes based on detection p-values:
the result is that comparisons between two methods in different papers may be based
on different pipelines (it should however be noted that the availability of such pipeline
“parameters” presents another opportunity for preferential reporting). In a similar vein,
we were required to make subjective decisions on whether different implementations of
similar algorithms constituted distinct or equal methods. Similarly, the evolution of a
method over time was also not taken into account. Authors often release new (hope-
fully improved) versions of packages implementing their methods; when twomethods are
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compared and then subsequently compared at a later time, the evaluations may not be
completely consistent, although likely lacking systematic bias.
Truly “neutral” authorship could also not be verified, as we are ignorant of any personal
feelings and connections our neutral-labelled authors may have, and extensive authorship
lists may have overlap we did not take into account. Most importantly, the interpretation
of the complex, multidimensional comparison of methods from the papers was very dif-
ficult. In particular, due to dependence patterns (within studies and between methods),
standard statistical inference (e.g., deriving confidence intervals for the above-mentioned
rates) was impossible. Despite these limitations, we feel this study convincingly illustrates
the issue of over-optimism and indicates that its order of magnitude is not negligible.
Solutions?
These observations highlight a disturbing issue: it is likely the results with regard to new
methods presented in the computational literature are considerably biased in favor of the
new method, and weaknesses of these new methods tend to be ignored. These biases and
omissions are a problem for readers who rely on this literature to select methods. This
situation calls for solutions at different levels of the scientific publishing process.
In an ideal world, authors would report the performance of their new methods in a
balanced and transparent manner. They would not cherry-pick their best results, for
example across a large set of results obtained through different configurations of datasets,
simulation scenarios, parameter settings, or performance metrics, while sweeping the
other results—those making the new method look less impressive—under the carpet. To
achieve this long-term goal, journal editors and reviewers have a major responsibility.
For authors to feel comfortable reporting balanced results and detailing the weaknesses
of their new methods, the acceptance of nuanced pictures and open statements must
increase. Editors and reviewers should become more tolerant towards methods that are
not reported to perform best universally: although “groundbreaking” discoveries occa-
sionally occur—i.e., a new method outperforms those existing in all respects—such a
scenario is unrealistic, and the expectation of such results engenders malpractice.
Even in the ideal world described above, however, bias in favor of the new method can-
not be completely eliminated, for example because the authors are more familiar with
their new method than with competing methods. Moreover, a significant move towards
this ideal world cannot realistically be achieved quickly. For these reasons, we believe
that users of methods would strongly benefit from more high-quality neutral compar-
ison studies, which tend to be more reliable than studies introducing a new method.
Here the general scientific community and the journals in particular can play a posi-
tive role by acknowledging that neutral method-comparison studies are valuable research
contributions—as some journals includingGenome Biology [12] have already started to do
in the last few years. This acknowledgment would relax the pressure on scientists to con-
stantly produce new methods, freeing them to objectively investigate the method—new
or existing—most appropriate to their data and research questions. That said, benchmark
studies alone are not enough. Users of methods should be educated in the proper inter-
pretation of benchmark studies: selecting methods requires expertise, and benchmark
studies give a limited picture of the situation in a specific context perhaps not relevant
to the given reader. For example, the choice of appropriate performance measures is
not easy; in the context of methylation data analysis, see the case of evaluation criteria
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related to the reduction of technical variation, which are widely used but of questionable
relevance [24].
More generally, researchers conducting benchmark studies have to make a myriad of
design choices that may substantially influence the final conclusion of the study. There
is no unique or gold-standard procedure for performing a high-quality benchmark study
on a given set of methods for a given question (hence the usefulness of the previously
mentioned meta-analyses of benchmark studies). Computational scientists must thus
redouble efforts in developing appropriate designs and reporting strategies for their com-
parison studies [2, 8], with the twin goals of more balanced reporting of newmethods and
an increase in the quality of neutral comparison studies.
In the meantime, scientists reading papers on new methods should keep in mind that
this literature is potentially strongly biased. As our parents likely told us, newer is not
always better.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13059-021-02365-4.
Additional file 1: Supplementary information. This document includes the following supplementary information:
supplementary methods, supplementary figures, supplementary tables, supplementary reference list.
Additional file 2: Data set (excel file). The excel data file data_set_of_extracted_data_Buchka_et_al.xlsx contains the
data from our bibliographical survey.
Additional file 3: Review history.
Acknowledgements
The authors thank Alethea Charlton for language corrections and Kasper Daniel Hansen and Rafael Irizarry for insightful
comments and helpful discussion.
Peer review information
Barbara Cheifet was the primary editor of this article and managed its editorial process and peer review in collaboration
with the rest of the editorial team.
Review history
The review history is available as Additional file 3.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was partly funded by grant BO3139/4-3 to ALB
from the German Research Foundation (DFG).
Authors’ contributions
SB conducted the survey and performed the data extraction and statistical analysis, PG and AH contributed to the study
concept, RW planned the survey, ALB coordinated the project, and ALB and RW wrote the manuscript. All authors edited
and approved the final manuscript.
Availability of data andmaterials
Data and R codes to reproduce the results are available from https://github.com/StefanBuchka/Papers [25].
Declarations
Ethics approval and consent to participate
Not relevant.
Competing interests
The authors declare that they have no competing interests.
Author details
1Institute for Medical Information Processing, Biometry and Epidemiology, LMU, Munich, Germany. 2Institute of Medical
Informatics, Statistics and Epidemiology, School of Medicine, TUM, Munich, Germany. 3Institute of General Practice and
Health Services Research, School of Medicine, TUM, Munich, Germany. 4Department of Biochemistry, University of Otago,
Otago, New Zealand. 5Research Unit Molecular Epidemiology, Institute of Epidemiology, Helmholtz Zentrum München,
German Research Center for Environmental Health, Neuherberg, Germany.
Buchka et al. Genome Biology          (2021) 22:152 Page 8 of 8
Received: 20 December 2020 Accepted: 23 April 2021
References
1. Boulesteix AL, Charlton A, Hoffmann S, Seibold H. A replication crisis in methodological research? Significance.
2020;7:18–21.
2. Boulesteix AL, Wilson R, Hapfelmeier A. Towards evidence-based computational statistics: lessons from clinical
research on the role and design of real-data benchmark studies. BMC Med Res Methodol. 2017;17(1):138.
3. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann
Intern Med. 2007;147(8):573–7.
4. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group
randomised trials. BMC Med. 2010;8(1):18.
5. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic
review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
6. Sauerbrei W, Abrahamowicz M, Altman DG, Cessie S, Carpenter J, on behalf of the STRATOSinitiative.
Strengthening analytical thinking for observational studies: the STRATOS initiative. Stat Med. 2014;33(30):5413–32.
7. Mangul S, Martin LS, Hill BL, Lam AKM, Distler MG, Zelikovsky A, et al. Systematic benchmarking of omics
computational tools. Nat Commun. 2019;10:1393.
8. Weber LM, Saelens W, Cannoodt R, Soneson C, Hapfelmeier A, Gardner PP, et al. Essential guidelines for
computational method benchmarking. Genome Biol. 2019;20(1):125.
9. Boulesteix AL, Lauer S, Eugster MJ. A plea for neutral comparison studies in computational sciences. PlOS ONE.
2013;8(4):e61562.
10. Kreutz C, Can NS, Bruening RS, Meyberg R, Mérai Z, Fernandez-Pozo N, et al. A blind and independent benchmark
study for detecting differeally methylated regions in plants. Bioinformatics. 2020;36(11):3314–21.
11. Gardner PP, Watson RJ, Morgan XC, Draper JL, Finn RD, Morales SE, et al. Identifying accurate metagenome and
amplicon software via a meta-analysis of sequence to taxonomy benchmarking studies. PeerJ. 2019;7:e6160.
12. Robinson MD, Vitek O. Benchmarking comes of age. Genome Biol. 2019;20(205).
13. Boulesteix AL, Stierle V, Hapfelmeier A. Publication bias in methodological computational research. Cancer Inf.
2015;14:11–9.
14. Yousefi MR, Hua J, Sima C, Dougherty ER. Reporting bias when using real data sets to analyze classification
performance. Bioinformatics. 2009;26(1):68–76.
15. Jelizarow M, Guillemot V, Tenenhaus A, Strimmer K, Boulesteix AL. Over-optimism in bioinformatics: an illustration.
Bioinformatics. 2010;26(16):1990–8.
16. Norel R, Rice JJ, Stolovitzky G. The self-assessment trap: can we all be better than average? Mol Syst Biol.
2011;7(537):2–3.
17. Marx V. Bench pressing with genomics benchmarkers. Nat Methods. 2020;17(3):255–8.
18. Mitchell K, Brito JJ, Mandric I, Wu Q, Knyazev S, Chang S, et al. Benchmarking of computational error-correction
methods for next-generation sequencing data. Genome Biol. 2020;21(1):1–13.
19. Gabere MN, Noble WS. Empirical comparison of web-based antimicrobial peptide prediction tools. Bioinformatics.
2017;33(13):1921–9.
20. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium Methylation 450K
technology. Epigenomics. 2011;3(6):771–84.
21. Wilhelm-Benartzi CS, Koestler DC, Karagas MR, Flanagan JM, Christensen BC, Kelsey KT, et al. Review of processing
and analysis methods for DNA methylation array data. Br J Cancer. 2013;109(6):1394.
22. Morris TJ, Beck S. Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data.
Methods. 2015;72:3–8.
23. Gardner PP, Paterson JM, McGimpsey S, Ashari-Ghomi F, Umu SU, Pawlik A, et al. Sustained software
development, not number of citations or journal choice, is indicative of accurate bioinformatic software.
bioRxiv:092205. 2021. https://www.biorxiv.org/content/10.1101/092205v3.
24. Fortin JP, Labbe A, Lemire M, Zanke BW, Hudson TJ, Fertig EJ, et al. Functional normalization of 450k methylation
array data improves replication in large cancer studies. Genome Biology. 2014;15:11.
25. Buchka S, Wilson R. On the optimistic performance evaluation of newly introduced bioinformatic methods. gitHub.
2021. https://github.com/StefanBuchka/Papers. Accessed 7 May 2021.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
